These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15804040)

  • 41. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
    Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhanced funding of pharmacoepidemiology through patenting the disclosure of adverse event information.
    Classen JB
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):390-3. PubMed ID: 16411171
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Reporting of side effects of drugs in the Netherlands].
    Meyboom RH
    Ned Tijdschr Geneeskd; 1986 Oct; 130(42):1879-83. PubMed ID: 3785453
    [No Abstract]   [Full Text] [Related]  

  • 44. [Report from abroad on side effects of drugs].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1994 Jan; 138(5):235-6. PubMed ID: 8114969
    [No Abstract]   [Full Text] [Related]  

  • 45. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 46. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 2010 Prescrire Information Awards.
    Prescrire Int; 2011 Mar; 20(114):82. PubMed ID: 21648236
    [No Abstract]   [Full Text] [Related]  

  • 48. Drug information: how much is too much? Suggestions for improving the sources of drug information.
    Devetski RL
    Indiana Med; 1986 Apr; 79(4):368-9. PubMed ID: 3711651
    [No Abstract]   [Full Text] [Related]  

  • 49. Peter Corr outlines Pfizer's approach to innovation, maximizing capabilities and delivering essential medicine. Interview by Steve Carney.
    Corr PB
    Drug Discov Today; 2005 Aug; 10(15):1017-20. PubMed ID: 16055016
    [No Abstract]   [Full Text] [Related]  

  • 50. Danger under the sugar coating.
    Salvage J
    Nurs Mirror; 1979 Jul; 149(3):10. PubMed ID: 257583
    [No Abstract]   [Full Text] [Related]  

  • 51. [Results in the identity tests of pharmaceutic specialties].
    Wenk R; Schmid J
    Pharm Prax; 1970; 8():183-4. PubMed ID: 5508935
    [No Abstract]   [Full Text] [Related]  

  • 52. [Drugs: 10 years of recall from the market].
    Bouvier-Colle MH
    Rev Epidemiol Sante Publique; 1994; 42(5):466-7. PubMed ID: 7973007
    [No Abstract]   [Full Text] [Related]  

  • 53. [The specifics of drug information].
    Böhm M
    Pharmazie; 1983 Aug; 38(8):556-8. PubMed ID: 6634927
    [No Abstract]   [Full Text] [Related]  

  • 54. [A searchable data bank on the Minitel system for iatrogenic pathology and drug interactions designed for practitioners].
    Escousse A; Bianchetti D; Sgro C; Parfait S; Perceau JP
    Therapie; 1987; 42(1):57. PubMed ID: 3590066
    [No Abstract]   [Full Text] [Related]  

  • 55. Drug companies monitor web chat for adverse reaction reports.
    Cross M
    BMJ; 2005 Jun; 330(7504):1347. PubMed ID: 15947382
    [No Abstract]   [Full Text] [Related]  

  • 56. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 57. Drug safety and drug toxicity: the Irish situation.
    Leonard B
    Ir Med J; 1987 Apr; 80(4):106-7. PubMed ID: 3597026
    [No Abstract]   [Full Text] [Related]  

  • 58. New countermeasures considered as drug counterfeiting grows.
    Schubert C
    Nat Med; 2008 Jul; 14(7):700. PubMed ID: 18607355
    [No Abstract]   [Full Text] [Related]  

  • 59. Drugs to avoid.
    Prescrire Int; 2011 Apr; 20(115):107. PubMed ID: 21648218
    [No Abstract]   [Full Text] [Related]  

  • 60. More lawyers. More bureaucrats. Less information on drug safety.
    Walker AM
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):394-5. PubMed ID: 16739244
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.